Yannick Marc Selected Research

Glutamyl Aminopeptidase (Aspartyl Aminopeptidase)

1/2022	QGC606: A Best-in-Class Orally Active Centrally Acting Aminopeptidase A Inhibitor Prodrug for Treating Heart Failure Following Myocardial Infarction.
1/2021	Brain ACE2 activation following brain aminopeptidase A blockade by firibastat in salt-dependent hypertension.
1/2020	Targeting Brain Aminopeptidase A: A New Strategy for the Treatment of Hypertension and Heart Failure.
1/2019	Brain renin-angiotensin system blockade with orally active aminopeptidase A inhibitor prevents cardiac dysfunction after myocardial infarction in mice.
1/2019	Specific Inhibition of Brain Angiotensin III Formation as a New Strategy for Prevention of Heart Failure After Myocardial Infarction.
1/2018	Central antihypertensive effects of chronic treatment with RB150: an orally active aminopeptidase A inhibitor in deoxycorticosterone acetate-salt rats.
8/2014	A new strategy for treating hypertension by blocking the activity of the brain renin-angiotensin system with aminopeptidase A inhibitors.
8/2012	Central antihypertensive effects of orally active aminopeptidase A inhibitors in spontaneously hypertensive rats.
10/2011	The role of the brain renin-angiotensin system in hypertension: implications for new treatment.
9/2008	Aminopeptidase A inhibitors as centrally acting antihypertensive agents.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yannick Marc Research Topics

Disease

9	Hypertension (High Blood Pressure) 08/2021 - 05/2008
4	Heart Failure 01/2022 - 01/2019
4	Myocardial Infarction 01/2022 - 03/2013
3	Fibrosis (Cirrhosis) 01/2022 - 01/2019
1	Cardiomegaly (Heart Hypertrophy) 01/2019
1	Infarction (Infarctions) 01/2019
1	Essential Hypertension 08/2012

Drug/Important Bio-Agent (IBA)

11	Glutamyl Aminopeptidase (Aspartyl Aminopeptidase)IBA 01/2022 - 05/2008
10	firibastatIBA 01/2022 - 09/2008
6	EnzymesIBA 01/2020 - 05/2008
5	Angiotensin IIIIBA 01/2020 - 05/2008
3	ProdrugsIBA 01/2022 - 08/2012
3	SaltsIBA 08/2021 - 01/2018
3	Antihypertensive Agents (Antihypertensives)IBA 01/2018 - 09/2008
2	Messenger RNA (mRNA)IBA 01/2022 - 01/2019
1	Connective Tissue Growth FactorIBA 01/2022
1	Ramipril (Altace)FDA LinkGeneric 01/2022
1	Enalapril FDA LinkGeneric 08/2021
1	Arginine Vasopressin (Argipressin)IBA 08/2021
1	Hydrochlorothiazide (Esidrix)FDA LinkGeneric 08/2021
1	CollagenIBA 01/2019
1	Losartan (Cozaar)FDA LinkGeneric 01/2019
1	AngiotensinsIBA 01/2018
1	ReninIBA 01/2018
1	Peptides (Polypeptides)IBA 10/2011